Skip to main content

ORIGINAL RESEARCH article

Front. Cell. Infect. Microbiol.
Sec. Molecular Viral Pathogenesis
Volume 14 - 2024 | doi: 10.3389/fcimb.2024.1468775
This article is part of the Research Topic Advances in Understanding Livestock and Poultry Coronavirus Infections: Mechanisms, Pathogenesis, and Control Strategies View all articles

Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine (SYS6006) in minks, cats, blue foxes and raccoon dogs

Provisionally accepted
Lei Shuai Lei Shuai 1,2*Hong Huo Hong Huo 1,2Jinming Wang Jinming Wang 1Chan Li Chan Li 3Shuang Xiao Shuang Xiao 1Han Wang Han Wang 1Jinying Ge Jinying Ge 1Gongxun Zhong Gongxun Zhong 1,2Zhiyuan Wen Zhiyuan Wen 1,2Chong Wang Chong Wang 1,2Qiaoling Lang Qiaoling Lang 3Lili Chen Lili Chen 3Chandler Wang Chandler Wang 1Jinliang Wang Jinliang Wang 1,2Xijun Wang Xijun Wang 1Xijun He Xijun He 2Yuntao Guan Yuntao Guan 2Zhigao Bu Zhigao Bu 1,2,4
  • 1 Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China
  • 2 National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin, China
  • 3 CSPC Pharmaceutical Group Limited, Shijiazhuang, Hebei Province, China
  • 4 Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, China

The final, formatted version of the article will be published soon.

    Minks, cats and some other species of carnivores are susceptible of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and have a high risk of transmitting SARS-CoV-2 to humans.The development of animal vaccines can be an effective measure to protect animals against SARS-CoV-2 and reduce the potential risk of human infection. We previously developed a messenger ribonucleic acid (mRNA) vaccine SYS6006 that has proven to be an efficient COVID-19 vaccine widely used in humans. Here, we further evaluated the safety and immunogenicity of SYS6006 as an animal COVID-19 vaccine candidate for SARS-CoV-2 susceptible animals or wild animals. SYS6006 was safe and immunogenic in mice, and completely protected mice against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. SYS6006 was able to induce neutralizing antibodies against the SARS-CoV-2 wild-type, Delta and Omicron BA.2 strain on day 7 after prime immunization, and two doses of immunization could enhance the neutralizing antibody responses and produce long-lasting potent antibodies for more than 8 months in minks and cats, blue s 删除[Lei Shuai]: foxes and raccoon dogs, while all immunized animals had no abnormal clinical signs during immunization. These results provided here warrant further development of this safe and efficacious mRNA vaccine platform against animal COVID-19.

    Keywords: SARS-CoV-2, mRNA vaccine, Safety, neutralizing antibody, Susceptible animals

    Received: 22 Jul 2024; Accepted: 27 Aug 2024.

    Copyright: © 2024 Shuai, Huo, Wang, Li, Xiao, Wang, Ge, Zhong, Wen, Wang, Lang, Chen, Wang, Wang, Wang, He, Guan and Bu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Lei Shuai, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.